PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche
Citations
6 citations
Cites background or methods from "PCSD1, a new patient-derived model ..."
...We showed that PCSD1 tumor cells were resistant to anti-androgen therapy specifically in the bone-niche [30]....
[...]
...Therefore, the PCSD1 intra-femoral xenograft model can be used to determine quantitatively the effects of current treatments such as enzalutamide and/or docetaxel on survival of prostate cancer cells in the spongy versus cortical boneniches and determine which of these niches may perhaps preferentially support prostate cancer stem cells or castrate-resistant prostate cancer cells [30]....
[...]
6 citations
5 citations
2 citations
1 citations
Cites background from "PCSD1, a new patient-derived model ..."
...In particular, highly aggressive carcinomas or colorectal and lung neoplasms have been proven to engraft efficiently, although the generation of PDTX from selective neoplasms remains largely challenging (ER/PR positive breast cancers) or virtually impossible (prostate cancers).(14-19) In the case of melanoma, Quitana et al(20) have originally demonstrated that PDTX can be established by a single cancer cell, and in the case of small‐cell lung cancers(21) and prostate(22) cancers, blood‐circulating tumor cells can be expanded in immunocompromised mice....
[...]
References
10,829 citations
3,875 citations
"PCSD1, a new patient-derived model ..." refers background in this paper
...Both have been shown to improve survival [8-11], however, eventually, resistance develops to these as well, perhaps through mutations in the androgen receptor [12]....
[...]
3,866 citations
2,046 citations
"PCSD1, a new patient-derived model ..." refers background in this paper
...Bicalutamide, one form of androgen deprivation, acts as a competitive inhibitor of androgens by binding the androgen receptor (AR), impairing DNA binding to Androgen Response Elements (ARE), and impairing recruitment of co-activators necessary for testosterone or DHT to impart their proliferative effect on responsive cells [5]....
[...]
1,083 citations
"PCSD1, a new patient-derived model ..." refers background in this paper
...Signaling cross-talk as a mechanism of castrate-resistance in prostate cancer that alters steroid hormone receptor activity and transcriptional regulation of gene expression has been demonstrated for AR in as well as other steroid hormone receptors such as GR [19-23]....
[...]